Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
How do you decide between Neoadjuvant (Checkmate 816) and Peri-adjuvant (Keynote 671) chemoimmunotherapy for early stage NSCLC?
Related Questions
In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?
Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?
Would you consider ALK-directed TKI for a ALK L1198F point mutation in a patient with metastatic lung adenocarcinoma after progressing through first line chemoimmunotherapy?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What are your top takeaways from ESMO 2023?
